Aurinia Pharmaceuticals (AUPH) EBITDA (2019 - 2026)

Aurinia Pharmaceuticals has reported EBITDA for 8 years, with the latest figure at $34.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 47.09% year-over-year to $34.1 million; the trailing twelve-month figure through Mar 2026 stood at $298.2 million (up 647.75% YoY), and the FY2025 full-year result was $287.2 million, up 4822.88% from the prior year.
• EBITDA for Q1 2026 stood at $34.1 million, down from $210.9 million in the prior quarter.
• The five-year high for EBITDA was $210.9 million in Q4 2025, with the low at -$38.4 million in Q1 2022.
• Historically, EBITDA has averaged $8.3 million across 5 years, with a median of -$8.7 million in 2022.
• Annual changes were most pronounced in 2023 — EBITDA plunged 54.38% — and 2025, when it soared 17975.75%.
• Aurinia Pharmaceuticals' EBITDA stood at -$25.6 million in 2022, then fell by 4.21% to -$26.7 million in 2023, then surged by 104.38% to $1.2 million in 2024, then soared by 17975.75% to $210.9 million in 2025, then slumped by 83.85% to $34.1 million in 2026.
• The last three EBITDA figures came in at $34.1 million (Q1 2026), $210.9 million (Q4 2025), and $31.7 million (Q3 2025), per Business Quant data.